A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- C. William Helm, MD
James Graham Brown Cancer Center
Principal Investigator - Carolyn Matthews, MD
Mary Crowley Medical Research Center
Principal Investigator - Dana Glenn, MD
Sharp Hospital
Principal Investigator - Deborah Armstrong, MD
Johns Hopkins Kimmel Cancer Center
Principal Investigator - Eric Winquist, MD
London Health Sciences Center
Principal Investigator - Ernst Lengyel, MD
University of Chicago
Principal Investigator - James Burke, MD
Billings Clinic (MCMRC network)
Principal Investigator - Krish Tewari, MD
UCI Medical Center
Principal Investigator - Mark Einstein, MD
Montefiore Medical Center
Principal Investigator - Michael Gold, MD
Oklahoma University Health Science Center
Principal Investigator - Michael Sawyer, MD
Cross Cancer Institute
Principal Investigator - Nikki Spellman, MD
Indiana University
Principal Investigator - Robert Holloway, MD
Florida Hospital Cancer Institute
Principal Investigator - Snehel Bhoola, MD
Memorial Health University Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tom Baker Cancer Center
Calgary, Alberta, Canada
- Cross Cancer Institute
Edmonton, Alberta, Canada
- London Health Sciences Center
London, Ontario, Canada
- Mcgill University Hospital
Montreal, Quebec, Canada
- Ucla Jccc Clinical Research Unit
Los Angeles, California, United States
- Uci Medical Center
Orange, California, United States
- Sharp Hospital
San Diego, California, United States
- Florida Hospital Cancer Institute
Orlando, Florida, United States
- Memorial Health University Medical Center
Savannah, Georgia, United States
- University of Chicago
Chicago, Illinois, United States
- Indiana University
Indianapolis, Indiana, United States
- James Graham Brown Cancer Center
Louisville, Kentucky, United States
- Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Billings Clinic (mcmrc Network)
Billings, Montana, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- Oklahoma University Health Science Center
Oklahoma City, Oklahoma, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Mary Crowley Medical Research Center
Dallas, Texas, United States
- Texas Oncology Pa, Presbyterian
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2007
- Primary completion
- 30 Apr 2008
- Completion
- 30 Apr 2008
- Last update posted
- 23 Aug 2012
- Registered enrollment
- 16
- Registry id
- NCT00516841
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.